Johnson Matthey saw revenue from (active pharmaceutical ingredients) APIs increase in fiscal 2015 despite competition from generic manufacturers and the relocation of a key customer.
The acquisition of Sigma-Aldrich by Merck KGaA could provide some opportunities for Johnson Matthey, the fine chemical company says as it reports a flat first half 2014/15.
Johnson Matthey’s API business had a mixed fiscal Q1 with gains made in ADHD ingredients and bulk opiates being accompanied by a decline in revenue from specialty opiates.
Johnson Matthey has completed restructuring its API unit and plans to pursue more generics industry business, after non-branded drug launches drove fine chemicals growth in fiscal 2014.
Johnson Matthey's metal scavenging system, Smopex, is designed to
remove precious metals at high speed from solutions and active
pharmaceutical ingredients (APIs).
Johnson Matthey has announced a reassuring business update ahead of
its 31 March year-end, suggesting that Adderall is the driving
force behind a recovery in its pharmaceutical materials business.
UK chemicals and metals firm Johnson Matthey has opened a precious
metal process catalyst manufacturing plant in India to cater to the
growing demand from the local pharmaceutical industry and provide a
springboard into other Asian...